BUSINESS
SRF: Safeguards against China’s dumping provide a cushion
The global phase-down of HFCs and the imposition of ADDs are expected to keep realisations from refrigerant gases firm. The near-term domestic demand trigger is the mandate for in-cabin ACs for commercial vehicles.
BUSINESS
What does the new US tariff salvo mean for Indian pharma?
The diktat could be positive for local generic drug companies
BUSINESS
Pace Digitek IPO is a play on energy storage opportunity
The company seems to be geared up for opportunities in the energy storage space. It aims to double BESS capacity to 10 GW in the next two years. It's also bidding for tenders in this space
BUSINESS
HEG: Will it benefit from the shift in China’s policy stance?
The anti-involution policy of China, which aims at curbing excessive competition among companies and reducing overcapacity, augurs well for HEG
BUSINESS
What's in store for Indian investors as Fed resumes the rate-cut cycle?
A tactical rebound in Indian equities and the rupee is likely
BUSINESS
What does the new US Biosecure draft Act mean for the Indian CRDMO industry?
Early enactment would compel the US biotech/pharma industry to cut reliance on China
BUSINESS
ITC: How does the new GST rate structure unfold for the cigarette business?
A flat GST on retail sales price will enhance pricing stability, and lower tax evasion, resulting in a predictable tax environment
BUSINESS
GST reforms: Push for natural ingredients in the flavours and fragrance industry
Lower GST rates for natural menthol and its derivatives, but higher for non-natural ingredients
BUSINESS
GST rate cuts to benefit players across the healthcare sector
Rates have been pruned for drugs used in chronic diseases as also medical devices and hospital chains
BUSINESS
Balaji Amines: Competitive intensity remains elevated
Favourable outcome of dumping probes appears to be the key growth catalyst in the near term
BUSINESS
Is the FMCG sector gearing up for another disruption?
Reliance Consumer Products Ltd (RCPL) is positioned to become a major disruptor in India's FMCG sector, with Reliance Industries announcing aggressive expansion plans
BUSINESS
Galaxy Surfactants: Valuation pricing in the pessimistic outlook
The company’s long-standing relations with MNC customers can help it navigate the US tariff headwinds
BUSINESS
Gem Aromatics IPO: A niche play on flavours and fragrances market
Key growth drivers will be the new set of product lines belonging to the aroma industry
BUSINESS
Zydus Lifesciences: Time to accumulate the stock?
Tariffs pose a near-term risk. However, Zydus’s focus on novel drugs and the foray into medical devices are key moves to watch
BUSINESS
Sai Life Sciences: Strong start keeps CDMO business in the lead
India’s limited share in the CRDMO market presents strong headroom for growth
BUSINESS
Why Indian exporters may not succeed in offsetting the potential US loss
Even as it faces a trade war with the US, China’s share in global exports has increased over the years. For India, replicating this story will not be easy
BUSINESS
Divi’s Lab: Better capex guidance to meet upcoming demand
R&D activities around peptides and contrast media remain the two medium-term growth drivers for the company. US tariffs are a near-term risk.
BUSINESS
SRF: Chemicals support the performance chemistry
The chemical business grew 24 percent YoY, helped by volume recovery in agrochemical intermediates and improved off-take for the recently launched products
BUSINESS
Acutaas Chemicals: CDMO business outlook improves
The CDMO business appears steady and additional approvals of indications for the oncology drug – Darolutamide – add to revenue visibility. Further, another key contract is expected to commence from Q4 FY26
BUSINESS
Navin Fluorine: After a strong run-up, is it time to book profit?
The company has multiple CDMO orders lined up for FY26, starting with two European majors, including US-based Fermion, for the second quarter.
BUSINESS
Sun Pharma: Innovative drugs are near-term growth drivers
Sun Pharma’s top line growth is steady. Innovative medicines to act as growth tonic, as the US generics business remains soft. The stock valuation is justified.
BUSINESS
Triple factors that are likely to guide the market course in the near term
How should investors position themselves amid Fed’s caution, IMF upgrades, and Trump’s punitive stance for India
BUSINESS
Laurus Labs: Is it time to book profit?
The company has a CDMO pipeline of 90+ human health projects, wherein 15 products are commercialised, targeting APIs and intermediates
BUSINESS
Syngene: How soon can it overcome near-term worries?
The CRDMO player is still to see the full impact of the client’s inventory rationalisation
